Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor
Biologic drugs are large molecule pharmaceuticals that do not cross the blood–brain barrier (BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered for BBB transport as IgG fusion proteins, where the IgG domain is a monoclonal antibody (MAb) that targets an endogeno...
Main Author: | William M. Pardridge |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/1/3 |
Similar Items
-
Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor
by: William M. Pardridge, et al.
Published: (2021-06-01) -
Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice
by: Demi M. Castellanos, et al.
Published: (2020-09-01) -
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
by: William M. Pardridge
Published: (2023-07-01) -
IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport
by: Ruben J. Boado
Published: (2022-07-01) -
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis
by: Hsueh-Yuan Chang, et al.
Published: (2021-01-01)